Free Design Audit Available - Click Here for Details

Axogen announces first surgical implant of Avive+ Soft Tissue Matrix

Axogen (Nasdaq:AXGN) this week announced the first surgical implantation of its Avive+ Soft Tissue Matrix.

Avive+ is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of nerve healing. The soft tissue matrix is processed and distributed as a 361 tissue product in accordance with FDA Good Tissue Practices under 21 CFR part 1271 regulations.

“We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” CEO and President Karen Zaderej said in a news release. “We are pleased with initial surgeon feedback and look forward to making Avive+ Soft Tissue Matrix available to more surgeons during our national launch, which is anticipated in the second quarter of 2024.”

Sign up for Blog Updates